Tarsus Pharmaceuticals (NASDAQ: TARS), Anavex Life Sciences (NASDAQ: AVXL), and MediciNova (NASDAQ: MNOV) all had recent positive news coming out of phase 2 clinical trials that should whet investors’ appetites.
Tarsus Pharmaceuticals (NASDAQ: TARS), Anavex Life Sciences (NASDAQ: AVXL), and MediciNova (NASDAQ: MNOV) all had recent positive news coming out of phase 2 clinical trials that should whet investors’ appetites.